REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo trial aims to reawaken immune system against stubborn lymphomas
Disease control Recruiting nowThis early-stage study is testing the safety and best dose of a two-drug combination for people with B-cell lymphomas that have come back or stopped responding to other treatments. The treatment pairs an immunotherapy drug (nivolumab) with a pill (ASTX727) that may help the immun…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Double-Punch trial aims to tame aggressive blood cancer
Disease control Recruiting nowThis study is testing whether combining two targeted cancer drugs is safe and effective for patients with an aggressive type of lymphoma that has come back or stopped responding to other treatments. The two drugs work together: one delivers a toxin directly to cancer cells, while…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New bridge therapy aims to get more patients to lifesaving CAR-T treatment
Disease control Recruiting nowThis study is testing a drug called odronextamab to see if it can help control aggressive lymphoma long enough for patients to receive CAR-T cell therapy, a potentially curative treatment. The drug is given before the process to collect immune cells for CAR-T begins, with the goa…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New combo therapy aims to rally immune system against tough lymphomas
Disease control Recruiting nowThis study is testing a combination of two drugs, epcoritamab and ibrutinib, for adults with aggressive B-cell non-Hodgkin lymphoma that has come back or stopped responding to previous treatments. The goal is to find a safe and effective dose. One drug helps the body's own immune…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Yazeed Sawalha • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New engineered immune cell therapy enters first human trials for aggressive blood cancers
Disease control Recruiting nowThis is an early-stage study testing a new type of personalized cell therapy called MC10029 for adults with B-cell blood cancers that have come back or stopped responding to standard treatments. Researchers will first find the safest dose and then see if the therapy can shrink tu…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
New hope for lymphoma patients who have run out of options
Disease control Recruiting nowThis study is testing whether a drug called loncastuximab tesirine can shrink tumors in adults with specific types of B-cell lymphoma that have come back or stopped responding to other treatments. The drug is designed to target cancer cells directly. Researchers will give the dru…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
Scientists test double punch against Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing whether adding one of two new drugs (tazemetostat or zanubrutinib) to an existing two-drug therapy works better for controlling an aggressive type of blood cancer called large B-cell lymphoma. It is for adults whose cancer has returned or did not respond to …
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New immune therapy trial aims to control Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing whether adding a new immune-boosting drug called epcoritamab to standard chemotherapy and a stem cell transplant can better control aggressive large B-cell lymphoma that has returned or not responded to prior treatment. It will involve about 25 adults whose …
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
Mega-Dose vitamin c joins fight against stubborn blood cancers
Disease control Recruiting nowThis study is testing if adding high-dose vitamin C (given through an IV) to standard chemotherapy can help patients whose lymphoma has returned or hasn't responded to treatment. It also tests vitamin C alone for certain pre-leukemia conditions. The goal is to see if vitamin C ma…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
Poop pills trial aims to boost cancer treatment success
Disease control Recruiting nowThis study is testing whether taking capsules containing healthy donor stool (fecal microbiome transplant) can improve gut health and treatment outcomes for adults with hard-to-treat lymphoma. All participants receive standard CAR-T cell therapy, a powerful cancer treatment, but …
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
Radiation 'Bridge' tested to boost powerful Cancer-Fighting cell therapy
Disease control Recruiting nowThis early study is testing if giving targeted radiation to all visible cancer sites is a safe and practical 'bridge' treatment for patients waiting for a powerful cell therapy called CAR T-cells. It is for adults with a fast-growing type of lymphoma that has returned or hasn't r…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC
-
New 5-Drug attack on Tough-to-Treat blood cancers
Disease control Recruiting nowThis study is testing a combination of five medications (called ViPOR) for people with aggressive types of B-cell lymphoma that have returned after treatment or did not respond to prior therapy. The goal is to see if this drug combination can effectively control the cancer and le…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
New CAR-T therapy trial targets Tough-to-Treat HIV-Related cancers
Disease control Recruiting nowThis early-stage study is testing a personalized immune therapy called axicabtagene ciloleucel (a type of CAR-T) for people with HIV who have an aggressive form of B-cell lymphoma that has returned or not responded to prior treatments. The main goals are to check if the treatment…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC
-
New drug combo aims to boost Last-Resort cancer treatment
Disease control Recruiting nowThis study is testing whether adding a new drug called odronextamab can improve the effectiveness of a powerful last-resort treatment (CAR-T therapy) for an aggressive type of blood cancer called DLBCL. The trial is for adults whose cancer has come back or hasn't responded to at …
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC
-
New combo therapy aims to boost Cancer-Killing power of CAR-T
Disease control Recruiting nowThis early-phase study is testing the safety and effectiveness of a new drug called ST-067 when given alongside a personalized immune cell therapy (CAR-T) for patients with aggressive large B-cell lymphoma that has come back or not responded to other treatments. The goal is to se…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 17, 2026 13:08 UTC
-
Scientists test 'Clean-Up' drugs to boost Cancer-Killing power of CAR T-Cell therapy
Disease control Recruiting nowThis study is for adults with aggressive B-cell lymphoma that has returned or not responded to prior treatments. After receiving a standard CAR T-cell therapy, patients whose cancer is still present but stable will be assigned to receive one of two additional drugs, both drugs, o…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC